Will ACC.26 Obicetrapib Data on Kidney, Safety and Lipids Change NewAmsterdam Pharma’s (NAMS) Narrative?

• NewAmsterdam Pharma announced it would present multiple Phase 3 and outcomes-related data sets for its oral CETP inhibitor obicetrapib at the ACC.26 cardiology meeting in New Orleans, highlighting kidney function, safety and lipid-related cardiovascular risk metrics in high‑risk patients.
• An interesting angle for investors is that obicetrapib is being positioned as a low‑dose, oral option intended to complement or expand existing LDL‑lowering approaches, with European commercialization rights already exclusively licensed to Menarini.
• We will now examine how the upcoming ACC.26 presentations on obicetrapib’s safety and efficacy shape NewAmsterdam Pharma’s broader investment narrative.

Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

What Is NewAmsterdam Pharma’s Investment Narrative?

For NewAmsterdam Pharma, the core belief you need as a shareholder is that obicetrapib can carve out a meaningful role alongside existing LDL‑lowering therapies, and that the company can translate its clinical package into approvals and commercial uptake despite ongoing losses. The ACC.26 data presentations fit neatly into that story: they keep obicetrapib’s Phase 3 safety, kidney function and risk‑marker profile in front of cardiologists ahead of the key PREVAIL cardiovascular outcomes readout and ongoing EMA review, but are unlikely to change the immediate catalyst stack on their own unless the detailed safety or outcomes‑adjacent signals surprise to the downside. With the share price pulling back in recent weeks despite strong one‑year returns, investors are still weighing long‑duration upside against execution risk, persistent cash burn and dilution or partnership terms outside Europe.

However, investors also need to weigh one particular risk that is easy to overlook.
Despite retreating, NewAmsterdam Pharma’s shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three fair value views from the Simply Wall St Community span from about US$48 to a very large figure, underlining how far opinions can stretch when a business like NewAmsterdam is still loss making and dependent on clinical and regulatory milestones. You are seeing that same tension in the near term, where enthusiasm around obicetrapib’s ACC.26 data sits alongside concerns about ongoing cash burn and the possibility of future capital raises, all of which can shape how the market rewards any clinical success.

Explore 3 other fair value estimates on NewAmsterdam Pharma – why the stock might be a potential multi-bagger!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Curious About Other Options?

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com